Consolidated Statement of Stockholders' Equity - USD ($)	Total	Amgen	Preferred Stock	Common Stock	Common Stock Amgen	Additional Paid-In Capital	Additional Paid-In Capital Amgen	Accumulated Other Comprehensive Income (loss)	Accumulated Deficit	Non-controlling Interest
Beginning Balance, Amount at Sep. 30, 2016	$ 95,024,259		$ 16	$ 162,116		$ 493,844,909		$ 7,449	$ (398,435,043)	$ (555,188)
Beginning Balance, Shares at Sep. 30, 2016			15,652	69,746,685
Stock-based compensation	7,891,595					7,891,595
Exercise of stock options, Amount	271,931			$ 136		271,795
Exercise of stock options, Shares				135,730
Common stock- Restricted Stock Units vesting, Amount	(403,261)			$ 481		(403,742)
Common stock- Restricted Stock Units vesting, Shares				481,212
Common stock issued		$ 12,420,000			$ 1,746		$ 12,418,254
Common stock issued, Shares					1,745,810
Preferred stock converted to common stock, Amount			$ (16)	$ 2,671		(2,655)
Preferred stock converted to common stock, Shares			(15,652)	2,670,989
Exercise of exchange rights, Amount	17,150			$ 5		17,145
Exercise of exchange rights, Shares				5,000
Foreign currency translation adjustments	25,783							25,783
Net income (loss)	(34,380,295)								(34,380,295)
Ending Balance, Amount at Sep. 30, 2017	80,867,162			$ 167,155		514,037,301		33,232	(432,815,338)	(555,188)
Ending Balance, Shares at Sep. 30, 2017				74,785,426
Stock-based compensation	8,454,607					8,454,607
Exercise of stock options, Amount	2,656,710			$ 605		2,656,105
Exercise of stock options, Shares				604,611
Exercise of warrants, Amount	1,237,429			$ 288		1,237,141
Exercise of warrants, Shares				288,473
Common stock- Restricted Stock Units vesting, Amount	(54,668)			$ 1,327		(55,995)
Common stock- Restricted Stock Units vesting, Shares				1,326,792
Common stock issued	56,585,035			$ 11,500		56,573,535
Common stock issued, Shares				11,500,000
Foreign currency translation adjustments	(54,796)							(54,796)
Net income (loss)	(54,450,478)								(54,450,478)
Ending Balance, Amount at Sep. 30, 2018	95,241,001			$ 180,875		582,902,694		(21,564)	(487,265,816)	(555,188)
Ending Balance, Shares at Sep. 30, 2018				88,505,302
Stock-based compensation	12,393,323					12,393,323
Exercise of stock options, Amount	$ 8,275,410			$ 1,543		8,273,867
Exercise of stock options, Shares	1,542,795			1,542,795
Common stock- Restricted Stock Units vesting, Amount				$ 2,197		(2,197)
Common stock- Restricted Stock Units vesting, Shares				2,197,305
Common stock issued	$ 60,521,729			$ 3,261		60,518,468
Common stock issued, Shares				3,260,869
Foreign currency translation adjustments	(370,060)							(370,060)
Net income (loss)	67,974,849								67,974,849
Ending Balance, Amount at Sep. 30, 2019	$ 244,036,252			$ 187,876		$ 664,086,155		$ (391,624)	$ (419,290,967)	$ (555,188)
Ending Balance, Shares at Sep. 30, 2019				95,506,271